TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28641582
Drug: IV phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV phenytoin infusion (20 mg/kg over 20 min)
Study: 18503138
Drug: Octostim nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octostim nasal spray (300 mug)
Study: 17027358
Drug: GnRH analogue
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogue (100 microg) administered to all individuals, followed by retesting of hormone levels after 4 hours.
Study: 17027358
Drug: hCG administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG administration for patients with beta-thalassemia and low T levels.
Study: 8838438
Drug: Loperamide with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide with cotrimoxazole (960 mg, twice daily for 24 h before and 48 h after administration)
Study: 8838438
Drug: Loperamide oxide
Normalized name: Loperamide oxide
DrugBank: Loperamide oxide (DB14661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide oxide with cotrimoxazole (960 mg, twice daily for 24 h before and 48 h after administration)
Study: 2938194
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ipratropium combined with 1.25 mg, 2.5 mg or 5.0 mg fenoterol
Study: 2938194
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg salbutamol
Study: 2938194
Drug: Combined preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined preparations (ipratropium and fenoterol)
Study: 27689549
Drug: Other treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatment conditions
Study: 23686640
Drug: GSD (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSD (oral glucose spray) - 10 puffs delivering 50 mg of glucose per puff
Study: 17944738
Drug: Low-volume 5-aminosalicylic
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume 5-aminosalicylic acid foam (2 x 1 g/30 mL)
Study: 17944738
Drug: High-volume 5-aminosalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume 5-aminosalicylic acid foam (2 x 1 g/60 mL)
Study: 9884941
Drug: Modified preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified preparation (13.9‐17.6 GBq 99mTcO4‐)
Study: 9884941
Drug: Regular preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular preparation (4.4‐8.8 GBq 99mTcO4‐)
Study: 7532938
Drug: Tranilast and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranilast and local treatment (nasal and tubal)
Study: 7532938
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment (control for Group A)
Study: 3061819
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of perindopril once daily
Study: 3061819
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of perindopril once daily
Study: 3061819
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of perindopril once daily
Study: 26073355
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Rosuvastatin tablet formulation 1
Study: 26073355
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Rosuvastatin tablet formulation 2
Study: 18082788
Drug: Pharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatment with fibrinolytics
Study: 18082788
Drug: Adjunctive therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapies including beta-blockers, aspirin (or clopidogrel if aspirin is contraindicated), nitroglycerin, and analgesia
Study: 18082788
Drug: Clopidogrel as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel as adjunctive therapy for patients undergoing fibrinolysis
Study: 18082788
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin and low-molecular-weight heparin as adjunctives
Study: 18082788
Drug: Multiple new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple new antithrombin agents
Study: 12817175
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg (DBPC trials)
Study: 12817175
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg (PROBE trials)
Study: 9105068
Drug: Salmeterol 100
Normalized name: fluticasone-salmeterol 100 mcg-50 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 100 microg twice a day
Study: 3888863
Drug: Naproxen 1000
Normalized name: naproxen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 1000 mg daily
Study: 8252318
Drug: Naproxen 1500
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 1500 mg daily
Study: 8252318
Drug: Naproxen combined
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen combined with 4 g paracetamol daily
Study: 8252318
Drug: Lower naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lower naproxen doses with paracetamol
Study: 3515924
Drug: Acetaminophen plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen plus codeine 650 mg + 60 mg
Study: 29116880
Drug: C. difficile
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. difficile vaccine
Study: 21911650
Drug: Subretinal gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal gene therapy using recombinant adeno‐associated virus 2 (rAAV2) carrying the RPE65 gene
Study: 21911650
Drug: Subretinal gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal gene therapy
Study: 20089951
Drug: Acyclovir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (400 mg orally twice daily)
Study: 17884802
Drug: Mandibular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular nerve block (MNB) with ropivacaine 10 mg ml(‐1)
Study: 11163559
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal saline injection)
Study: 9661575
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 50 mg/kg preoperatively and 8 mg.kg‐1.h‐1 intraoperatively
Study: 8697927
Drug: Lansoprazole (L)
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole (L)
Study: 29956034
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy (Habit reversal training and exposure response prevention)
Study: 29956034
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy (Habit reversal training and exposure response prevention)
Study: 29956034
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (Individual and Group)
Study: 27716668
Drug: Potentially Inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially Inappropriate Medications (PIM) identified using the Priscus list
Study: 27716668
Drug: PIM prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIM prescription rates
Study: 19639690
Drug: Intranasal electrophoresis
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal electrophoresis using mexidol
Study: 17910224
Drug: 16% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16% carbamide peroxide gel
Study: 17910224
Drug: 30% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% carbamide peroxide gel
Study: 15851743
Drug: Nighttime pergolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nighttime pergolide (1 mg)
Study: 11805862
Drug: Serotonin agonist
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin agonist (buspirone hydrochloride)
Study: 8750367
Drug: High-dose aerosolized
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aerosolized pentamidine prophylaxis (300 mg twice a month or 600 mg once a month)
Study: 8750367
Drug: Standard-dose aerosolized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose aerosolized pentamidine prophylaxis (300 mg once a month)
Study: 8750367
Drug: High-dose aerosolized
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aerosolized pentamidine prophylaxis (300 mg twice a month)
Study: 8750367
Drug: High-dose aerosolized
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aerosolized pentamidine prophylaxis (600 mg once a month)
Study: 8750367
Drug: High-dose aerosolized
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aerosolized pentamidine prophylaxis
Study: 6995186
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg griseofulvin-FP daily for 8 weeks
Study: 31950977
Drug: Histamine-2 Receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine-2 Receptor Blockers (H2RBs)
Study: 31003878
Drug: Chemotherapy-induced peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-induced peripheral neuropathy (CIPN) assessment and management communication
Study: 26990171
Drug: Lubiprostone 24
Normalized name: LUBIPROSTONE 24MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone 24 μg BID
Study: 22934930
Drug: NAL prescription
Normalized name: Foster & Thrive All Day Allergy Original Prescription Strength 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAL prescription for hearing aids
Study: 22934930
Drug: DSL prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSL prescription for hearing aids
Study: 19969160
Drug: Ultrasonography-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonography-guided injection of 20 mg triamcinolone mixed with 1.5 mL 2% lidocaine and 4 mL normal saline followed by 5 weekly injections of sodium hyaluronate
Study: 19969160
Drug: Blind injection
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind injection of 20 mg triamcinolone mixed with 1.5 mL 2% lidocaine and 4 mL normal saline followed by 5 weekly injections of sodium hyaluronate
Study: 14998846
Drug: PLD 50
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD 50 mg/m2 (every 4 weeks)
Study: 14998846
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m2 (every 3 weeks)
Study: 9532992
Drug: Transcervical amnioinfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcervical amnioinfusion of 500 mL saline over 30 minutes, then 500 mL at 30 drops per minute
Study: 2684660
Drug: Ketamine 2
Normalized name: esketamine 28 mg nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2 mg kg‐1 i.v. followed by a ketamine infusion of 2 mg kg‐1 h‐1
Study: 28070862
Drug: CAM2038 q4w
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM2038 q4w 96 mg
Study: 28070862
Drug: CAM2038 q4w
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM2038 q4w 192 mg
Study: 28070862
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine 8, 16, or 24 mg daily for 7 days
Study: 28070862
Drug: CAM2038 q1w
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM2038 q1w 16 mg
Study: 19465880
Drug: Fluoxetine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine alone (n = 109)
Study: 19465880
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy alone (n = 111)
Study: 19465880
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (n = 107)
Study: 16959450
Drug: Lidocaine-prilocaine (EMLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine (EMLA patch 5%)
Study: 8141714
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (SK) and subcutaneous heparin
Study: 8141714
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (SK) and intravenous heparin
Study: 8141714
Drug: Tissue plasminogen
Normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tissue plasminogen activator (t‐PA) and intravenous heparin
Study: 8141714
Drug: Combination t‐PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination t‐PA and SK
Study: 2469654
Drug: Electrolyte solution
Normalized name: electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte solution
Study: 29590007
Drug: Low-dose Abiraterone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Abiraterone (250 mg with a low-fat meal)
Study: 29590007
Drug: Standard-dose Abiraterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose Abiraterone (1,000 mg fasting)
Study: 29590007
Drug: Low-dose Abiraterone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Abiraterone
Study: 29590007
Drug: Standard-dose Abiraterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose Abiraterone
Study: 27421538
Drug: Oral 17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17β‐estradiol 1 mg/d
Study: 25161816
Drug: Short-term psychotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term psychotherapy (psychodynamic or solution-focused)
Study: 18755584
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-Fluorouracil (5-FU) based first-line chemotherapy
Study: 12532114
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (mattress and pillow encasings)
Study: 12490967
Drug: Ciprofibrate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate (100 mg once daily for 16 weeks)
Study: 9873260
Drug: HIV-infected patients
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-infected patients with haemophilia A with inhibitors
Study: 9873260
Drug: HIV-infected patients
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-infected patients with haemophilia A without inhibitors
Study: 8138763
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of raised serum cholesterol concentration (> or = 6.5 mmol/l) after education intervention
Study: 8138763
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of normal serum cholesterol concentration (< 5.2 mmol/l) after education intervention
Study: 3273841
Drug: Antenatal phenobarbital
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal phenobarbital (700 mg loading dose, followed by daily maintenance until delivery)
Study: 28346285
Drug: Prompt revascularization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt revascularization with percutaneous coronary intervention or coronary artery bypass grafting in addition to intensive medical therapy
Study: 21621227
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) intervention called Managing Anxiety and Depression using Education and Skills (MADES)
Study: 14673543
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (88 mEq in 50 ml) administered as a slow bolus 1 hour prior to (201)Tl injection
Study: 9433652
Drug: grepafloxacin 600
Normalized name: grepafloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: grepafloxacin 600 mg after fasting or after consumption of a standard high-fat meal
Study: 9433652
Drug: grepafloxacin 400
Normalized name: grepafloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: grepafloxacin 400 mg alone or after infusion of famotidine 20 mg
Study: 11103175
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg kg‐1
Study: 8499200
Drug: Pethidine 0.67
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 0.67 mg kg‐1
Study: 8499200
Drug: Methadone 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 0.1 mg kg‐1
Study: 30544211
Drug: Maternal intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal intervention with fish-oil capsules (215 mg DHA + 285 mg EPA)
Study: 30544211
Drug: Child intervention
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child intervention with fish-oil-enriched complementary food (169 mg DHA + 331 mg EPA)
Study: 28651304
Drug: Rifaximin and
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin and Propranolol combination therapy
Study: 2049686
Drug: Propranolol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol monotherapy
Study: 19738166
Drug: Panitumumab or
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab or Cetuximab (EGFR-targeted monoclonal antibodies)
Study: 12760990
Drug: Fentanyl effect-site
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl effect-site concentration of 0.8 ng/mL
Study: 12760990
Drug: Fentanyl effect-site
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl effect-site concentration of 1.0 ng/mL
Study: 12760990
Drug: Fentanyl effect-site
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl effect-site concentration of 1.4 ng/mL
Study: 12760990
Drug: Fentanyl effect-site
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl effect-site concentration of 2.0 ng/mL
Study: 12760990
Drug: Fentanyl effect-site
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl effect-site concentration of 3.0 ng/mL
Study: 10998082
Drug: Triflusal (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal (600 mg day‐1 for 5 days)
Study: 9417748
Drug: Reviparin (7000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reviparin (7000 U bolus before PTCA, followed by 10,500 U infusion over 24 hours, then 3500 U s.c. twice a day for 28 days)
Study: 9417748
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10,000 U unfractionated heparin bolus followed by 24,000 U infusion over 24 hours, then 28 days of s.c. placebo injections)
Study: 8171218
Drug: Rifaximin cream
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin cream
Study: 8171218
Drug: Oxytetracycline cream
Normalized name: Oxytetracycline
DrugBank: Oxytetracycline (DB00595)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytetracycline cream
Study: 3463571
Drug: 0.02% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% chlorhexidine (CH) as the irrigating solution
Study: 3463571
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as the irrigating solution
Study: 30157388
Drug: Ibudilast (≤100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibudilast (≤100 mg daily)
Study: 24614693
Drug: Polyphenol-rich whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-rich whole food supplement (blend of pomegranate, green tea, broccoli, and turmeric)
Study: 23512638
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg (non-Chinese)
Study: 23512638
Drug: Ustekinumab 45
Normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 45 mg (Chinese)
Study: 23512638
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg (Chinese)
Study: 23512638
Drug: Ustekinumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (both doses in Chinese)
Study: 20693186
Drug: Genotype-guided dosing
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided dosing algorithm for warfarin treatment
Study: 20693186
Drug: Clinical information
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical information only dosing algorithm for warfarin treatment
Study: 18030007
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy prior to external beam radiation therapy
Study: 18030007
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy prior to prostatectomy
Study: 18030007
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy for 6 or 8 months prior to prostatectomy